Navigation Links
QRxPharma Initiates Second Pivotal Phase 3 Study of MoxDuo(TM)IR Dual-Opioid(TM) for NDA Submission
Date:2/10/2010

Evaluate Analgesic Efficacy and Safety of MoxDuo(TM)IR in Patients with Moderate to Severe Post-Operative Pain Following Total Knee Replacement Surgery

SYDNEY and BEDMINSTER, N.J., Feb. 10 /PRNewswire/ -- QRxPharma Limited (ASX: QRX and OTCQX: QRXPY) announced today initiation of its second pivotal Phase 3 registration trial (Study 009) to evaluate analgesic efficacy and safety of MoxDuo™IR, a patented 3:2 ratio fixed dose combination of morphine plus oxycodone.  This two-arm study will compare the effectiveness and safety of a flexible MoxDuo™IR dose regimen to a fixed low dose for managing moderate to severe pain in patients who have undergone total knee replacement surgery.  The Company expects to complete dosing in Q3 2010 in preparation for filing a New Drug Application (NDA) with the US Food and Drug Administration in Q4 2010. MoxDuo™IR targets the acute pain market, a $2.5 billion segment of over $7 billion spent annually on prescription opioids in the US.

"In support of our Phase 3 program, clinical trials conducted to date have consistently demonstrated MoxDuo™IR achieves as good or better pain relief with fewer incidences of moderate-severe side effects than morphine, oxycodone or Percocet®. Based on these data, we are optimistic about the competitive advantages of MoxDuo," said Dr. John Holaday, Managing Director and Chief Executive Officer, QRxPharma.  "With the initiation of the Company's second pivotal trial for MoxDuo™IR, we are one step closer to definitively proving the value of our Dual-Opioid™ product to potential partners, prescribers and patients."

In 2009, an open-label pilot study demonstrated improved analgesia of flex
'/>"/>

SOURCE QRxPharma Limited
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. QRxPharma Doses First Patients in Phase III Clinical Trial Program for its Dual Opioid Pain Therapy
2. QRxPharma Releases Successful Phase 3 Study Results for Dual Opioid Pain Therapy
3. QRxPharma Releases Additional Phase 3 Data for Q8003IR Dual Opioid Pain Therapy
4. QRxPharma Successfully Completes Comparative Study for Dual-Opioid(TM) Pain Therapy
5. QRxPharma Inks Deal with Patheon for the Manufacture of MoxDuo(TM)CR
6. QRxPharma Limited Announces A$21.6 Million Fully Underwritten Capital Raising
7. Carrington Subsidiary DelSite Initiates Critical Toxicology Studies of Its Nasal Powder Bird Flu Vaccine
8. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
9. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
10. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
11. MedImmune Initiates Phase 2a Multi-Dose Study in Patients with Asthma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2015)... 2015  New York College of Health Professions announces ... portfolio with U.S. Patent #8,996,098 donated by its Chairman ... a surgical instrument that allows surgeons to view and ... in the traditional format of a slide that is ... during surgery, thus providing the surgeon real time analysis ...
(Date:4/1/2015)... ASPEN, Colo. , April 1, 2015  Astellas ... (CKF), is pleased to sponsor the second annual Bounce ... award, which will recognize two transplant recipients who exhibit ... a career accomplishment, participation in a sport or hobby, ... loved ones. "The Bounce Back Award ...
(Date:4/1/2015)... 2015  The fairness of the proposed acquisition of ... Pharmaceutical Industries ("Teva") is being investigated by WeissLaw LLP, ... investigation focuses on possible breaches of fiduciary duty and ... of ASPX for agreeing to sell the Company to ... definitive agreement for Teva to acquire ASPX in a ...
Breaking Medicine Technology:Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 2Ground-Breaking Surgical Instrument Allows Surgeons to obtain Real Time Biopsies 3Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 2Astellas Teams Up with The Chris Klug Foundation on the Bounce Back Award to Recognize Extraordinary Transplant Recipients 3WeissLaw LLP: Auspex Pharmaceuticals Inc. Acquisition By Teva Pharmaceutical Industries May Not Be In The Best Interest of ASPX Shareholders 2
... Recent Highlights: Qutenza ® (capsaicin) ... adoption by large US institutions; 238 hospitals purchased as of 4Q10, ... Q4 2010 revenue totaled $2.3 million including $0.5 million U.S. Qutenza ... in 17 countries at December 31, 2010 NGX-1998 Phase 2 ...
... March 30, 2011 Rochester Medical Corporation (Nasdaq: ... BioSciences N.V. today approved the previously announced sale of ... subsidiary to Rochester Medical Corporation. Rochester Medical ... and under the terms of the Share Purchase Agreement ...
Cached Medicine Technology:NeurogesX Reports Fourth Quarter and Year-End 2010 Results 2NeurogesX Reports Fourth Quarter and Year-End 2010 Results 3NeurogesX Reports Fourth Quarter and Year-End 2010 Results 4NeurogesX Reports Fourth Quarter and Year-End 2010 Results 5NeurogesX Reports Fourth Quarter and Year-End 2010 Results 6NeurogesX Reports Fourth Quarter and Year-End 2010 Results 7NeurogesX Reports Fourth Quarter and Year-End 2010 Results 8NeurogesX Reports Fourth Quarter and Year-End 2010 Results 9Fornix Shareholders Approve the Sale of Laprolan B.V. to Rochester Medical Corporation 2
(Date:4/1/2015)... The Pennsylvania Court overseeing a mass ... ) has scheduled a meeting for April 13th, ... of Common Pleas, the meeting will commence at 9:30 ... indicate that the proceeding will address the progress of ... who experienced gynecomastia (male breast growth) and other complications ...
(Date:4/1/2015)... 01, 2015 EAGAN, Minn. (April 1, ... its family of companies (Blue Cross) today announced audited ... year with net income of $61.5 million, reflecting positive ... organization reported a net operating loss of $8.2 million ... operating margin of one-tenth of one percent (0.1%). ...
(Date:4/1/2015)... Parents of teenaged and adolescent children might want ... post discusses Teen Violence Related to Substance Abuse. As ... Awareness Month, the substance abuse treatment center has issued ... identify if there may be problems with their kids ... alcohol. , “People learn how to establish healthy relationships ...
(Date:4/1/2015)... FL (PRWEB) April 01, 2015 South ... received Provisional Certificate of Authority (PCOA) approval from the ... step in the ongoing development of a retirement community ... individual health, wellness and spiritual development. , America’s aging ... to meet the housing needs of seniors, according to ...
(Date:4/1/2015)... eMindful , the provider of ... executive team with the addition of veteran digital marketing ... , In his new role, Suissa is leading the ... the business and consumer portals. He also is leading ... online community. His hiring was a result of ...
Breaking Medicine News(10 mins):Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 2Health News:Pennsylvania Court Overseeing Hundreds of Risperdal Lawsuits Schedules April Meeting 3Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 2Health News:Blue Cross and Blue Shield of Minnesota Reports 2014 Results 3Health News:Best Drug Rehabilitation Issues Toolkit for Teen Violence Related to Substance Abuse 2Health News:Casa Sant’Angelo Receives Approval for New Retirement Living 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 2Health News:Addressing The Growing Demand for Interactive, Internet Mindfulness Programs, eMindful Expands Leadership Team With Top Digital Marketing Executive 3
... Researchers say a greater awareness is needed about the risks ... age, they often have // multiple chronic conditions and take ... people as they age. ,Researchers conducted a study to ... at 765 prescriptions , more than 20 percent of the ...
... (TEP), is an incision between the trachea and esophagus ... silicone valve , researchers say this new surgical technique ... patients who have had their voice box and tongue ... operative speech rehabilitation therapy, can provide understandable speech communication ...
... Researchers say nearly one-third of patients don’t get a ... for systolic heart failure, a condition in which the ... to their research they say that those who don’t ... to die within one year than those who do ...
... at detecting cancers in women at high risk of developing ... ,The study involved around 1,900 women with a lifetime breast ... who also carried one of the genes known to put ... the women received a clinical breast exam every six months ...
... people with inhalation anthrax is needed to minimize the ... someone who has anthrax from someone who just has ... question that has remained unanswered. ,That’s the question ... 47 cases of anthrax -- including 11 cases blamed ...
... experience migraine headaches compared with one in 20 adult men. ... same time as menstruation each month. Many women claim they ... new study confirms this happens. ,Researchers analyzed data ... shows that in the five days before menstruation, women were ...
Cached Medicine News:
The ICP-Monitor for intraventricular, intraparenchymal and epidural measurement of intracranial pressure and for measuring cerebral perfusion pressure and compliance....
... The CODMAN ICP ... accurate measurements of intracranial ... parenchymal or intraventricular levels. ... electronically rather than through ...
The Optical Tracking System provides a complete solution for image-guided surgery. Precision tracking technology converges with powerful visualization software for optimal surgical planning and navig...
Penfield Dissector #2...
Medicine Products: